Research · Sep 3, 2026
[ISRG] Intuitive Surgical Thesis 2026: da Vinci 5 Refresh Cycle Defends Against Medtronic Hugo + J&J Ottava
Intuitive Surgical FY2025 revenue ~$9B (+18%) with ~2.7M procedures (+17% YoY) across urology + general surgery + gynecology + thoracic + cardiac. da Vinci 5 (March 2024 launch) driving multi-year platform refresh cycle — Xi → 5 upgrades plus new placements. Installed base ~9,500 systems globally. Razor/blade economics: Instruments+Accessories 58% of revenue scales with procedures. Ion bronchoscopy platform reached $220M (+30% growth, 120K procedures). FY2026 thesis: da Vinci 5 + procedure expansion (general surgery + emerging cardiac/thoracic) + Ion scaling drives ~$11-12B revenue by FY2027; key competitive risks: Medtronic Hugo FDA approval pending (already commercial international, ~20-30% pricing discount vs da Vinci), J&J Ottava launch FY2027-2028 ironically founded by Frederic Moll (Intuitive co-founder) via Auris Health acquired by J&J.